StockNews.com Initiates Coverage on CEL-SCI (NYSE:CVM)

Equities researchers at StockNews.com assumed coverage on shares of CEL-SCI (NYSE:CVM) in a research report issued to clients and investors on Wednesday. The brokerage set a “sell” rating on the stock.

CEL-SCI Trading Down 7.9 %

CVM opened at $0.37 on Wednesday. The firm has a 50 day simple moving average of $0.63 and a 200 day simple moving average of $0.95. CEL-SCI has a fifty-two week low of $0.36 and a fifty-two week high of $3.08. The company has a market cap of $24.33 million, a price-to-earnings ratio of -0.63 and a beta of 0.65. The company has a debt-to-equity ratio of 1.00, a current ratio of 0.64 and a quick ratio of 0.18.

Hedge Funds Weigh In On CEL-SCI

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in CVM. Calton & Associates Inc. bought a new position in CEL-SCI during the 3rd quarter worth approximately $50,000. Black Diamond Financial LLC lifted its holdings in CEL-SCI by 35.8% during the second quarter. Black Diamond Financial LLC now owns 72,000 shares of the company’s stock worth $84,000 after acquiring an additional 19,000 shares in the last quarter. Plotkin Financial Advisors LLC acquired a new position in CEL-SCI in the third quarter valued at about $98,000. Thoroughbred Financial Services LLC increased its holdings in shares of CEL-SCI by 140.9% in the second quarter. Thoroughbred Financial Services LLC now owns 136,761 shares of the company’s stock worth $158,000 after acquiring an additional 80,001 shares in the last quarter. Finally, Renaissance Technologies LLC increased its holdings in shares of CEL-SCI by 29.9% in the second quarter. Renaissance Technologies LLC now owns 173,800 shares of the company’s stock worth $202,000 after acquiring an additional 40,000 shares in the last quarter. Institutional investors own 12.08% of the company’s stock.

About CEL-SCI

CEL-SCI Corporation, a clinical-stage biotechnology company, engages in the research and development of immune system therapy for the treatment of cancer and other diseases in the United States. The company's lead immunotherapy is Multikine, which has completed Phase 3 clinical trials for the potential treatment of certain head and neck cancers.